Last reviewed · How we verify
NCT02504840
Natural History of Multiple Sclerosis and Its Mimickers
trial in Neurologic Disorders in 104 participants. Completed in 5 March 2020.
5 March 2020
Quick facts
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 104 |
| Start date | 23 July 2015 |
| Primary completion | 5 March 2020 |
| Estimated completion | 5 March 2020 |
| Sites | 1 location across United States |
Conditions studied
- Neurologic Disorders — all drugs for Neurologic Disorders →
- Healthy Volunteers — all drugs for Healthy Volunteers →
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Who can join
18 and older, any sex, with Neurologic Disorders or Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: \- Magnetic resonance imaging (MRI) has been used for decades to help diagnose and monitor neurological disorders like multiple sclerosis (MS). Researchers want to improve how MRI pictures are taken. They also want to learn more about using newer MRIs with stronger magnets to get better pictures than standard MRIs provide. Objectives: \- To collect data that will help researchers better understand MS and related diseases. Eligibility: * Adults 18 and older with MS or MRI findings that appear similar to MS, or with other neurological diseases that may look or act like MS. * Healthy adult volunteers. Design: * Participants will be screened with a review of their medical records. * Participants will have a baseline visit. It will include a physical exam, medical history, and neurological exam. They may have blood tests. * The study will last indefinitely. * Participants may have MRIs. Some MRIs may include a contrast dye. For this, a needle will be used to guide a thin plastic tube into an arm vein. * Participants may have up to 2 lumbar punctures per year. Skin will be numbed and a needle inserted between back bones will remove fluid. * Participants may give saliva samples and have an eye exam. * Participants may have evoked potential tests. These measure how the nervous system responds to different types of stimulation. Participants may sit in front of a TV and watch pictures on the screen. Or they may wear earphones that make a clicking noise or static. Or they may get a small electrical shock that may tingle and cause a hand or foot twitch. * Participants may have tests of strength, spasticity, sensations, balance, and/or walking.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI.
Absinta M, Ha SK, Nair G, Sati P, et al · · 2017 · cited 481× · PMID 28971799 · DOI 10.7554/elife.29738
Verify or expand the search:
- PubMed search for NCT02504840
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurologic Disorders
Currently open trials in the same condition.
- NCT04684602 — Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions · Phase 1, PHASE2 · recruiting
- NCT00271622 — The Neurodevelopmental and Behavioral Phenotyping Screening Protocol · recruiting
- NCT00060541 — Evaluation and Treatment of Neurosurgical Disorders · recruiting
Other National Institute of Neurological Disorders and Stroke (NINDS) trials
Trials by the same sponsor.
- NCT07137442 — Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniques · recruiting
- NCT02522611 — Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain · Phase 1, PHASE2 · not yet recruiting
- NCT07511049 — Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study · Phase 2 · not yet recruiting
- NCT07416188 — Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma · Phase 1, PHASE2 · not yet recruiting
- NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02504840 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Neurological Disorders and Stroke (NINDS)
- Last refreshed: 14 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02504840.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing